Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.34 |
| ▸ | CNR1 | P21554 | 7/20 | 0.33 |
| ▸ | CNR2 | P34972 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23502468 | 0.89 | TLR7 (0.39) | TLR7TLR8KDM4ENPC1ALDH1A1 | |
| SCHEMBL20047597 | 0.77 | CNR2 (0.33) | TLR8CNR1CNR2 | |
| SCHEMBL20047567 | 0.76 | CNR2 (0.35) | TLR7TLR8CNR1CNR2KDM4E | |
| SCHEMBL20047579 | 0.75 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL20047581 | 0.74 | TLR8 (0.32) | TLR7TLR8CNR1CNR2KCNH2 | |
| SCHEMBL23502590 | 0.74 | CNR2 (0.39) | CNR1CNR2 | |
| SCHEMBL20047665 | 0.74 | CNR2 (0.39) | CNR1CNR2 | |
| SCHEMBL20047686 | 0.74 | CNR2 (0.34) | TLR8CNR1CNR2 | |
| SCHEMBL20047608 | 0.73 | CNR2 (0.38) | CNR1CNR2KDM4EALDH1A1MAPT | |
| SCHEMBL25101222 | 0.72 | TSHR (0.44) | TLR7TLR8KDM4ENPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10450306-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | TLR7 491/4885TLR8 901/4885CNR1 410/4885 |
| US-20180099957-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | GPBAR1, SLC10A1, NR1H4 | TLR7 491/4885TLR8 901/4885CNR1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.